

REVIEW

Melatonin action in *Plasmodium* infection: Searching for molecules that modulate the asexual cycle as a strategy to impair the parasite cycle

Pedro H. S. Pereira | Celia R. S. Garcia 

Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil

Correspondence

Célia R. S. Garcia, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Email: cgarcia@usp.br

Funding information

Fundação de Amparo à Pesquisa do Estado de São Paulo, Grant/Award Number: 17/08684-7 and 18/07177-7

Abstract

Half of the world's population lives in countries at risk of malaria infection, which results in approximately 450,000 deaths annually. Malaria parasites infect erythrocytes in a coordinated manner, with cycle durations in multiples of 24 hours, which reflects a behavior consistent with the host's circadian cycle. Interference in cycle coordination can help the immune system to naturally fight infection. Consequently, there is a search for new drugs that interfere with the cycle duration for combined treatment with conventional antimalarials. Melatonin appears to be a key host hormone responsible for regulating circadian behavior in the parasite cycle. In addition to host factors, there are still unknown factors intrinsic to the parasite that control the cycle duration. In this review, we present a series of reports of indole compounds and melatonin derivatives with antimalarial activity that were tested on several species of *Plasmodium* to evaluate the cytotoxicity to parasites and human cells, in addition to the ability to interfere with the development of the erythrocytic cycle. Most of the reported compounds had an IC₅₀ value in the low micromolar range, without any toxicity to human cells. Triptosil, an indole derivative of melatonin, was able to inhibit the effect of melatonin in vitro without causing changes to the parasitemia. The wide variety of tested compounds indicates that it is possible to develop a compound capable of safely eliminating parasites from the host and interfering with the life cycle, which is promising for the development of new combined therapies against malaria.

KEYWORDS

antimalarials, melatonin, *Plasmodium*, synchronicity

1 | *PLASMODIUM FALCIPARUM* LIFECYCLE AND DRUG RESISTANCE

Malaria is caused by a protozoan of the genus *Plasmodium*, and the species *P. falciparum* is responsible for the most serious human parasitic disease. It is estimated that 3.3

billion people live in areas at risk of infection and 216 million cases were reported in 2017, leading to more than 450,000 deaths.¹ The asexual cycle of *P. falciparum* occurs in the human host, with infection initiated by the bite of the female *Anopheles* mosquito, which injects sporozoites together with saliva in the host.² Once in the bloodstream, sporozoites migrate to the liver and invade hepatocytes,

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. *Journal of Pineal Research* published by John Wiley & Sons Ltd

where they can remain inactive or replicate asexually, forming a large number of merozoites in the host cell.^{3,4} The release of merozoites into circulation marks the beginning of the erythrocytic stages (Figure 1). Merozoites invade erythrocytes and develop within the parasitophorous vacuole, undergoing various biochemical and morphological transformations, which can be identified by three stages referred to as ring, trophozoite and schizont.⁵ Young trophozoites, also called “rings” because of their morphology, are small and have low metabolic activity until they develop into fully grown trophozoites. In the trophozoite stage, metabolic activity is high and there is an increase in cell volume and hemoglobin digestion in preparation for schizogony. In the schizont stage, the parasite undergoes multiple DNA replication steps and successive mitotic

divisions. At this point, newly formed merozoites wait to exit the host cell simultaneously. Mature forms of the erythrocyte stages adhere to endothelial cells to avoid contact with the immune system in the spleen.⁶ The rupture of erythrocyte releases all internal contents, including new merozoites, into the bloodstream, allowing for reinvasion of red blood cells and a continuation of the intraerythrocytic cycle. The simultaneous rupture of erythrocytes causes an intense peak in the immune response every 24 or 48 hours, which is a clinical feature of *Plasmodium* infection with symptoms including high fever and chills at well-defined intervals that coincide with the duration of the intraerythrocytic cycle.^{7,8} Protozoan erythrocyte invasion, their development within the cell, and erythrocyte rupture occur in a coordinated manner, such that all parasites complete




FIGURE 1 *Plasmodium falciparum* intraerythrocytic cell cycle. The life cycle of *Plasmodium falciparum* begins with the bite of a female *Anopheles* mosquito, which injects a small amount of saliva containing parasites into the bloodstream. At this stage, the parasite is called a sporozoite, and they migrate through the bloodstream to the liver where they invade hepatocytes. Sporozoites within hepatocytes develop until they differentiate into schizonts. Schizonts divide by asexual reproduction, generating merozoites, which are the phase responsible for erythrocyte invasion. After invasion, the merozoites differentiate into rings (or young trophozoites). The rings gradually increase in cell volume and metabolism, until they become mature trophozoites. At this stage, there is an increase in DNA replication and preparation for schizogony (asexual cell division). The multinucleate stage is called a schizont, and it develops until the segmentation of the multiple nuclei and the formation of new merozoites occurs. The rupture of schizonts releases more merozoites into the bloodstream, which invade new erythrocytes and continue the erythrocytic cycle. A small percentage of merozoites at schizont stage are committed to differentiate into gametocytes after parasite invasion to RBCs. The factors that determine which, when and how many merozoites participate in this process are not well established to date. Gametocytes develop within erythrocytes for approximately 15 days and through 5 different stages until they are captured by a female *Anopheles* mosquito during feeding

the cycle at a well-defined time of day.⁹ The most accepted hypothesis for this phenomenon is that the simultaneous release of parasites into the bloodstream can provide protection against the host immune system.⁹⁻¹¹

During reinfection of erythrocytes, a small percentage of merozoites differentiate into gametocytes, the infective stage of the mosquito vector.¹² The mechanism that determines which parasites will undergo this process is still unclear, but it is known that some host cues play an essential role in this differentiation process. It takes 10-12 days and five morphological stages of maturation until a gametocyte-committed merozoite can invade an erythrocyte and differentiate into a single mature male or female gametocyte, which remains circulating in peripheral blood vessels for several days. During mosquito feeding, gametocytes are ingested and complete their maturation into gametes inside the mosquito intestine, after which fertilization and zygote formation occur.¹³ The zygote migrates to the intestinal epithelium, where it develops into an oocyst. The rupture of the oocyst releases sporozoites, which migrate to the salivary gland and are injected into the human bloodstream during mosquito feeding, completing the cycle.¹⁴

For several decades, the fight to control malaria has been challenged by the emergence of parasites that are resistant to antimalarials used on a large scale. First, the appearance of chloroquine resistance compromised this effective treatment, which was followed successively by resistance to sulfadoxine + pyrimethamine, mefloquine, and, more recently, artemisinins. Mefloquine + artesunate-based therapy, one of the first artemisinin derivatives, began being replaced in 2007 after an increasing number of treatment failures; it was substituted by the combination of piperaquine (PPQ) + dihydroartemisinin (DHA).^{15,16} The first warning signs for PPQ + DHA came in 2009, when reports that patients were taking longer than expected to respond to treatment began, which culminated in the failure of first-line treatment with PPQ + DHA in recent years.¹⁷

One of the main reasons for the recent reduction in the number of malaria cases is the excellent clinical efficacy of combined artemisinin therapies (ACTs), which have been adopted worldwide as a first-line treatment, together with the growing number of mosquito vector control measures.¹ However, treatment with ACTs faces an obstacle due to the increasing number of artemisinin-resistant parasites that have emerged and spread throughout South-East Asia. ACTs, in turn, led to the failure of DHA and PPQ in Cambodia, where parasites are now resistant to both drugs.^{18,19} Therefore, there is an urgent need to identify alternative drugs that can be used in mass treatment campaigns to reduce the local burden of malaria and block the spread of resistant strains. The main objective is to eliminate malaria from this region completely before resistance

spreads to Africa, where it would have devastating consequences for public health.^{20,21}

2 | MELATONIN ACTION IN *PLASMODIUM FALCIPARUM* INFECTION: SEARCHING FOR MOLECULES THAT MODULATE THE ASEXUAL CYCLE AS A STRATEGY TO IMPAIR THE PARASITE CYCLE

The in vivo maturation process of the parasite occurs in an extremely coordinated way, in which the schizonts rupture, releasing merozoites that invade new erythrocytes in a highly synchronized manner at intervals of 24 hours, depending on the *Plasmodium* species.¹¹ This means that for rupture and invasion events to occur simultaneously in different cells, the parasites must develop through the intraerythrocytic stages in a coordinated manner so that at the end of the cycle, the vast majority of schizonts are ready to rupture at the same time. The host hormone melatonin can modulate the synchrony of parasite development in the rodent *Plasmodium chabaudi* and the human parasite *Plasmodium falciparum*. Of note, pinealectomized mice infected by *P. chabaudi* lose the ability to synchronize. Interestingly, the nonsynchronous rodent malaria parasites are not affected by melatonin, as was previously reported in studies using *P. yoelli* and *P. berghei* as models.²²

Plasmodium falciparum protein kinase 7 (PfPK7) is an orphan kinase with no orthologs in mammalian cells. The C-terminal PfPK7 region displays similarity to the protein kinase activated by mitogen kinase (MAPKK), while the N-terminal region has similarity to the fungal protein kinase A.²³ The pfpk7 gene knockout has a slow parasite growth phenotype that is caused by a reduction in the number of merozoites in each cycle.²⁴ The exposure of the PfPK7 knockout strain (PfPK7-) to melatonin does not alter the proportion of asexual stages.²⁵ Recently, a comparative study of the PfPK7- and Pf3D7 strain phosphoproteomes was carried out in schizonts, resulting in the identification of 3,875 phosphorylation sites in 1,047 proteins.²⁶ In addition to PfPK7, the *P. falciparum* eukaryotic translation initiation factor kinase (Pfeik1) has been recently identified as another central kinase that transduces melatonin signaling in melatonin-induced parasite synchronization.²⁷ The roles and potential cross-activation of the Pfeik1 and PfPK7 kinases in parasite synchronization remain interesting questions to be investigated. Of interest, the activation of protein kinase A (PKA) in downstream melatonin signaling pathways occurs in both *P. falciparum*²⁸ and *P. chabaudi*.²⁹ Decoding how the above kinases interact to culminate in parasite cell cycle progression is an interesting




FIGURE 2 Melatonin signaling pathway in *Plasmodium falciparum*. Melatonin binds to an unknown receptor on the parasite membrane. Signaling depends on the action of a PLC that produces IP_3 . IP_3 binds to another unknown receptor in the endoplasmic reticulum and causes the release of Ca^{2+} from the organelle into the cytoplasm. Ca^{2+} activates a series of effector proteins, such as proteases and kinases, that control gene expression and cell cycle progression. PK7 plays an essential role, regulating gene expression and the ubiquitin proteasome system. Steps that can be pharmacologically inhibited with the effect of altering the parasite cell cycle are highlighted in red. 2-APB: 2-aminoethyl diphenylborinate; AC: Adenylate cyclase; ATP: Adenosine triphosphate; BTZ: bortezomib; cAMP: cyclic adenosine monophosphate; DAG: diacylglycerol; eIF: eukaryotic initiation factor; ER: endoplasmic reticulum; IP_3 : inositol 1,4,5-triphosphate; IP_3R : IP_3 receptor; Mel: melatonin; MelR: melatonin receptor; PIP2: phosphatidylinositol 4,5-bisphosphate; PK7: protein kinase 7; PKA: protein kinase A; PKI: protein kinase A inhibitor; PLC: phospholipase C; PVM: parasitophorous vacuole membrane; RBCM: red blood cell membrane; SERCA: sarco/endoplasmic reticulum Ca^{2+} -ATPase; Ub: ubiquitin; UPS: ubiquitin proteasome system

open question that could lead to new ways to block the malaria cycle (Figure 2).

Employing transcriptomic methodology such as RNA-Seq, Lima et al (2016) reported that melatonin modulates the expression of 38 genes in the 3D7 wild-type parasite strain compared to PfPK7-knockout parasites.³⁰ The genes in the ubiquitin proteasome system (UPS) were among those with altered expression.³¹ Relatedly, the PfNFYB transcription factor is one of the targets of melatonin-induced ubiquitination in *P. falciparum*.^{32,33} In addition, the action of melatonin on the mitochondrial dynamics of *P. falciparum* has also been reported. Melatonin is able to modulate the expression of three genes (two GTPase dynamins, PfDYN1 and PfDYN2, and the mitochondrial fission protein PfFIS1) possibly related to mitochondrial fission in a stage-specific manner.³⁴ Melatonin can increase the expression of PfDYN1 and PfFIS1, which could suggest that accelerated cell cycle progression occurs via the regulation of mitochondrial distribution to new cells.

The mechanism of melatonin signal transduction in *P. falciparum* involves the activation of phospholipase C, which promotes the generation of inositol triphosphate (IP_3), leading

to an increase in the cytosolic Ca^{2+} .³⁵ The known IP_3 receptor sequences are widely used in bioinformatics techniques as probes to search for uncharacterized receptors. However, all attempts to identify these receptors in apicomplexan parasites have failed and a canonical candidate for the *Plasmodium* IP_3 receptor has not been identified.³⁶

Temporarily controlled administration of melatonin can be used as a form of treatment for physiological disorders.³⁷⁻⁴¹ Melatonin can act as an intracellular antioxidant, participating in the processes of aging and the formation of free radicals, and its high concentration in the mitochondria of eukaryotic cells supports these roles.⁴²⁻⁴⁵ In fact, mitochondrial concentrations of melatonin are not affected by extracellular concentrations, and there are reports that purple bacteria, which gave rise to the mitochondria of modern eukaryotes, are capable of producing this hormone.^{46,47}

Recently, the periodicity of two *Plasmodium* species cycles and their relationship with the host's circadian clock were analyzed, aiming to separate parasite-intrinsic aspects from the host-specific aspects contributing to cell cycle regulation. Filipa Rijo-Ferreira et al (2020) identified a

relationship between the *Plasmodium chabaudi* circadian clock and the transcriptional regulation of a group of 174 genes that peak every 18 hours, indicating a parasite-intrinsic mechanism of cell cycle regulation.⁴⁸ However, this periodicity does not explain synchronization in a population, only in isolated parasites. Similarly, Lauren M. Smith et al (2020) identified the harmonic expression of a set of genes in *P falciparum* that was equivalent to half the duration of the cell cycle and resulted in two peaks of expression. In addition, the results were consistent with strains that have different total intraerythrocyte cycle durations.⁴⁹ Both of these studies showed that there is an intrinsic biological clock that renders individual parasites capable of regulating the duration of the erythrocytic cycle; however, at the population level, aspects of the host may be necessary. One of the genes that have a circadian expression pattern, serpentine receptor 10 (SR10), is a promising candidate as a key to link aspects of the host with the intrinsic clock of the parasites; knockout of this gene shortens the *P chabaudi* cycle to 2-3 hours and various cellular processes are deregulated, such as DNA replication and the ubiquitin proteasome system.⁵⁰

3 | MELATONIN AND ITS DERIVATIVES AS ANTIMALARIALS

Melatonin and derivatives of melatonin have been shown to affect malarial infection. In vivo experiments using luzindole in combination with suboptimal doses of chloroquine have shown promise; treatment of mice with luzindole and chloroquine has shown a clear synergistic effect, in which 25% of the animals remained alive on day 10 after treatment with chloroquine or luzindole individually, while 75% remained alive when the two drugs were administered together. There was also a decrease in parasitemia when the two drugs were used together compared to each drug separately, and as luzindole is not toxic to the parasite, the synergistic effect can be attributed to their ability to interfere with the synchronization of the erythrocytic cycle and improve the effectiveness of the host immune system.²²

It is important to note that the indole precursors of melatonin, such as serotonin, N-acetyl serotonin, and tryptamine, also affect the development of the intraerythrocytic cycle in a similar way. By contrast, IAA (indole 3-acetic acid), another indole compound that regulates several physiological processes in plants, is not able to interfere in the erythrocytic cycle. While melatonin and N-acetyl serotonin increase the expression of UPS genes, IAA does not, and instead, it decreases the expression of cullin (PF08_0094), another gene in that system. These data indicate that there is a degree of specificity in this class of compounds as regulators of different functions in the cell cycle of *P falciparum*.⁵¹

Recently, Dias, B. K. M. et al (2020) reported the potential of ten new synthetic indole derivatives as antimalarials by investigating their ability to act as agonists or antagonists of a putative melatonin receptor in *P falciparum*. While growth inhibition occurred at low micromolar levels, the compound melatotsil was identified as a potential agonist of a putative melatonin receptor in *P falciparum*. The characteristic effects of increased *P falciparum* parasitemia after treatment with melatonin were evident after treatment with melatotsil. In addition, coincubation of melatonin and melatotsil inhibited the expected effect, which indicates competition between the two molecules for the same target. By contrast, the compound triptotsil had no effect on parasitemia but was able to abolish the effect of melatonin.²⁷

Teguh et al (2013) characterized a series of conjugated quinoline and indole compounds that had antimalarial activity, demonstrating a mechanism of action that differed from those observed with quinolines, such as chloroquine, which likely affected mitochondrial functions via changes in the membrane potential of these organelles.⁵²

Fernandez et al (2009) reported on indole alkaloids extracted from *Fliersia* sp. using HPLC and tested the antimalarial activity of these compounds against *P falciparum* strains resistant to chloroquine and in cytotoxicity assays using HEK293 cells. The results indicated that three compounds were capable of inhibiting parasite growth by 50% at concentrations between 80 nM and 142 nM, and one compound, dimethylisoborreverine, had a potency comparable to artemisinin, with an IC₅₀ of 20 nM.⁵³

A series of compounds derived from triazine-indole were synthesized by Kgonkong et al (2005) and tested for antimalarial capacity. The group concluded that the addition of a trifluoromethyl group was responsible for the IC₅₀ of 30 nM in both resistant and chloroquine-sensitive strains, a value that is similar to that of mefloquine. Removal of the trifluoromethyl group causes the compound to have no antimalarial activity, raising the IC₅₀ value to 0.4 mM.⁵⁴

Agarwal et al (2005) synthesized 24 indole compounds and tested the ability of each to inhibit parasite maturation. Six compounds containing N-methyl piperazine have been described as ring substitutes with good antimalarial activity, capable of inhibiting ring maturation in schizonts. The compounds were 10 times more effective than pyrimethamine in preventing the erythrocyte cycle from maturing.⁵⁵

Another set of indole derivatives was tested by Schuck et al (2014), who investigated their toxicity and ability to interfere with the intraerythrocytic cycle of *P falciparum* in vitro in a similar role to that of melatonin. Two compounds have shown promise, N-[2-(1H-indol-3-yl)ethyl]hexanamide and N-[2-(1H-indol-3-yl)ethyl]benzamide; they are able to block synchronization caused by the addition of melatonin to parasite culture, while being unable to modulate cycle progression on their own. In addition, three other derivatives

have shown promise as new structures for the development of toxic derivatives, with IC₅₀ values on the order of 10 μ M and the possibility to insert structural modifications capable of decreasing this value further.⁵⁶

Using reactions designed based on the structure of melatonin and derived compounds, Luthra et al (2019) developed a new class of antimalarials based on arylalkanimino tryptamine derivatives. Several compounds with antimalarial activity have been found in the low micromolar/high nanomolar range capable of blocking the erythrocytic cycle at the trophozoite stage and melatonin-induced growth synchronization in parasite populations. In addition, binding studies indicated that some of the compounds tested were still capable of interacting with the human melatonin receptor MT₁.⁵⁷

Archibald L. Svogie et al (2015) described a new class of indole-derived antimalarials with promising activity, indolyl-3-ethanone- α -thioethers. Their screening highlighted two compounds with good antimalarial activity, 1-(1H-indol-3-yl)-2-[(4-nitrophenyl)thio]ethanone (IC₅₀, 240 nM) and 1-(5-chloro-1H-indol-3-yl)-2-[(4-bromophenyl)thio]ethanone (IC₅₀, 90 nM), both with no toxicity in HeLa cells.⁵⁸ Several other indole derivatives were synthesized by Lunga et al (2018), resulting in two new candidates with antimalarial activity, 1-(5-chloro-1H-indol-3-yl)-2-[(4-cyanophenyl)thio]ethanone and 1-(5-chloro-1H-indol-3-yl)-2-[(4-nitrophenyl)thio]ethanone. These two compounds had effects comparable to chloroquine, with IC₅₀s in the range of 30 nM. All of the compounds tested had no toxicity in HeLa cells or hemolytic activity.⁵⁹

Inhibitors of several tRNA synthetases present in *Plasmodium* are promising drug targets and have been well explored for the development of alternative therapies.⁶⁰⁻⁶⁶ There are two compartmentalized tryptophanyl-tRNA synthetases (TrpRS) in *P. falciparum*: one cytoplasmic molecule that participates in eukaryotic tRNA binding, and one that is directed to the apicoplast that participates in bacterial tRNA synthesis. The presence of a bacterial TrpRS in *P. falciparum* highlights a drug-like target already used by antibiotics against both Gram-positive and Gram-negative bacteria, which is of low toxicity in humans. Indolmycin, an indole similar to tryptophan, used as an inhibitor of TrpRS in the apicoplast has an IC₅₀ on the order of 1 micromolar when the parasite is exposed to the compound for 96 hours.⁶⁷ The high efficacy only after 96 hours indicates a mechanism of "late death" that is typical of drugs that affect the apicoplast, and this is of great relevance for combined treatment with fast-acting drugs, such as artemisinins.⁶⁸⁻⁷¹

4 | CONCLUSIONS

The growing reports of multidrug-resistant *Plasmodium* parasites and first-line drug treatment failures put pressure

on the scientific community to seek new drugs or alternative treatments to combat malaria. One option is the use of compounds capable of interfering with the duration and coordination of *Plasmodium* intraerythrocytic cycle. These compounds would disrupt the coordination of the cycle and consequently allow the host immune system to be more effective at combating infection. They do not necessarily need to be toxic to parasites, but they should potentiate the effect of antimalarials currently used to bypass resistance and result in more effective treatments, as was demonstrated with luzindole.²² Melatonin stands out as a host factor capable of interfering with the parasite cycle. Thus, indole compounds and melatonin derivatives have been explored as potential new antimalarial candidates.

The indole derivatives melatotsil and triptosil showed clear agonist and antagonist effects, respectively, to melatonin, and they are excellent starting points for the intelligent design of drugs capable of interfering with the coordination of the intraerythrocytic cycle. Several tested indole compounds have resulted in the inhibition of parasite growth in the nanomolar range, which is comparable with the antimalarials used today. Among them, triazine-indole and indole alkaloids stand out.^{53,54} In addition, there are also indole compounds capable of causing "late death" by affecting the synthesis of proteins in the apicoplast, which increases interest in their use in therapies combined with fast-acting drugs, such as artemisinin.

Currently, there are many indole compound structures with some antimalarial activity, and the presence of various mechanisms of action and different targets shows that this class of compounds is promising for the development of new drugs. Whether with a toxic effect on the parasite or interference in the coordination of the cycle, these compounds are promising candidates to circumvent resistance to antimalarials.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

PHSP and CRSG involved in conceptualization, draft preparation, writing, review, and editing; CRSG acquired funding. Both authors have read and agreed to the published version of the manuscript.

ORCID

Celia R. S. Garcia  <https://orcid.org/0000-0003-2825-1701>

REFERENCES

1. World Health Organization. World Malaria Report 2018 Isbn 978 92 4 156565 3. WHO. 2018.
2. Ménard R, Tavares J, Cockburn I, Markus M, Zavala F, Amino R. Looking under the skin: The first steps in malarial infection and immunity. *Nat Rev Microbiol*. 2013;11(10):701-712.

3. Tavares J, Formaglio P, Thiberge S, et al. Role of host cell traversal by the malaria sporozoite during liver infection. *J Exp Med*. 2013;210(5):905-915.
4. Prudêncio M, Rodriguez A, Mota MM. The silent path to thousands of merozoites: The Plasmodium liver stage. *Nat Rev Microbiol*. 2006;4(11):849-856.
5. Grüning C, Heiber A, Kruse F, Ungefehr J, Gilberger TW, Spielmann T. Development and host cell modifications of Plasmodium falciparum blood stages in four dimensions. *Nature Communications*. 2011;2(1). <http://dx.doi.org/10.1038/ncomms1169>
6. Spillman NJ, Beck JR, Goldberg DE. Protein export into malaria parasite-infected erythrocytes: mechanisms and functional consequences. *Annu Rev Biochem*. 2015;84(1):813-841.
7. Reece SE, Prior KF, Mideo N. The life and times of parasites: rhythms in strategies for within-host survival and between-host transmission. *J Biol Rhythms*. 2017;32(6):516-533.
8. Rund SSC, O'Donnell AJ, Gentile JE, Reece SE. Daily rhythms in mosquitoes and their consequences for malaria transmission. *Insects*. 2016;7(2):14.
9. Mideo N, Reece SE, Smith AL, Metcalf CJE. The Cinderella syndrome: Why do malaria-infected cells burst at midnight? *Trends Parasitol*. 2013;29(1):10-16.
10. Hotta CT, Gazarini ML, Beraldo FH, et al. Calcium-dependent modulation by melatonin of the circadian rhythm in malarial parasites. *Nat Cell Biol*. 2000;2(7):466-468.
11. Garcia CR, Markus RP, Madeira L. Tertian and quartan fevers: temporal regulation in malarial infection. *J Biol Rhythms*. 2001;16(321):436-443.
12. Joice R, Nilsson SK, Montgomery J, et al. Plasmodium falciparum transmission stages accumulate in the human bone marrow. *Sci Transl Med*. 2014;6(244):244re5.
13. Bansal A, Molina-Cruz A, Brzostowski J, et al. PfCDPK1 is critical for malaria parasite gametogenesis and mosquito infection. *Proc Natl Acad Sci*. 2018;115(4):774-779.
14. Graumans W, Tadesse FG, Andolina C, et al. Semi-high-throughput detection of Plasmodium falciparum and Plasmodium vivax oocysts in mosquitoes using bead-beating followed by circumsporozoite ELISA and quantitative PCR. *Malaria Journal*. 2017;16(1). <http://dx.doi.org/10.1186/s12936-017-2011-9>
15. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. *Am J Trop Med Hyg*. 2007;77(6 suppl):181-192.
16. Wongsrichanalai C, Meshnick SR. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. *Emerg Infect Dis*. 2008;14(5):716-719.
17. Ménard D, Fidock DA. Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia. *Lancet Infect Dis*. 2019;19(9):916-917.
18. Duru V, Khim N, Leang R, et al. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations. *BMC Med*. 2015;13:305.
19. Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: A multisite prospective cohort study. *Lancet Infect Dis*. 2016;16(3):357-365.
20. Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. *Nat Med*. 2017;23(8):917-928.
21. Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. Artemisinin Action and Resistance in Plasmodium falciparum. *Trends Parasitol*. 2016;32(9):682-696.
22. Bagnaresi P, Markus RP, Hotta CT, Pozzan T, S. Garcia CR. Desynchronizing Plasmodium Cell Cycle Increases Chloroquine Protection at Suboptimal Doses. *Open Parasitol J*. 2008;2(1):55-58.
23. Dorin D, Semblat JP, Pouillet P, et al. PfPK7, an atypical MEK-related protein kinase, reflects the absence of classical three-component MAPK pathways in the human malaria parasite Plasmodium falciparum. *Mol Microbiol*. 2005;55(1):184-196.
24. Dorin-Semblat D, Sicard A, Doerig C, Ranford-Cartwright L, Doerig C. Disruption of the PfPK7 gene impairs schizogony and sporogony in the human malaria parasite Plasmodium falciparum. *Eukaryot Cell*. 2008;7(2):279-285.
25. Koyama F, Ribeiro R, Garcia J, Mauro F, Chakrabarti D, Garcia C. Ubiquitin Proteasome System and the atypical kinase PfPK7 are involved in melatonin signaling in Plasmodium falciparum. *J Pineal Res*. 2013;53(2):147-153.
26. Pease BN, Huttlin EL, Jedrychowski MP, et al. Characterization of Plasmodium falciparum Atypical Kinase PfPK7-Dependent Phosphoproteome. *Journal of Proteome Research*. 2018;17(6):2112-2123. <http://dx.doi.org/10.1021/acs.jproteome.8b00062>
27. Dias BKM, Nakabashi M, Alves MRR, et al. The Plasmodium falciparum eIK1 kinase (PfeIK1) is central for melatonin synchronization in the human malaria parasite. Melatonin blocks melatonin action on parasite cell cycle. *Journal of Pineal Research*. 2020;69(3). <http://dx.doi.org/10.1111/jpi.12685>
28. Beraldo FH, Almeida FM, da Silva AM, Garcia CRS. Cyclic AMP and calcium interplay as second messengers in melatonin-dependent regulation of Plasmodium falciparum cell cycle. *J Cell Biol*. 2005;170(4):551-557.
29. Gazarini ML, Beraldo FH, Almeida FM, Bootman M, Da Silva AM, Garcia CRS. Melatonin triggers PKA activation in the rodent malaria parasite Plasmodium chabaudi. *J Pineal Res*. 2011;50(1):64-70.
30. Lima WR, Tessarin-Almeida G, Rozanski A, et al. Signaling transcript profile of the asexual intraerythrocytic development cycle of Plasmodium falciparum induced by melatonin and cAMP. *Genes Cancer*. 2016;7(9-10):323-339.
31. Koyama FC, Azevedo MF, Budu A, Chakrabarti D, Garcia CRS. Melatonin-Induced Temporal Up-Regulation of Gene Expression Related to Ubiquitin/Proteasome System (UPS) in the Human Malaria Parasite Plasmodium falciparum. Hardeland R, ed. *Int J Mol Sci*. 2014;15(12):22320-22330.
32. Lima WR, Moraes M, Alves E, Azevedo MF, Passos DO, Garcia CRS. The Pfnf-YB transcription factor is a downstream target of melatonin and cAMP signalling in the human malaria parasite Plasmodium falciparum. *J Pineal Res*. 2013;54(2):145-153.
33. Lima WR, Martins DC, Parreira KS, et al. Genome-wide analysis of the human malaria parasite Plasmodium falciparum transcription factor Pfnf-YB shows interaction with a CCAAT motif. *Oncotarget*. 2017;8(69):113987-114001.
34. Scarpelli PH, Tessarin-Almeida G, Viçoso KL, et al. Melatonin activates FIS1, DYN1, and DYN2 Plasmodium falciparum related-genes for mitochondria fission: Mitoemerald-GFP as a tool to visualize mitochondria structure. *Journal of Pineal Research*. 2019;66(2):e12484. <http://dx.doi.org/10.1111/jpi.12484>
35. Alves E, Bartlett PJ, Garcia CRS, Thomas AP. Melatonin and IP3-induced Ca²⁺ release from intracellular stores in the malaria

- parasite *Plasmodium falciparum* within infected red blood cells. *J Biol Chem*. 2011;286(7):5905-5912.
36. Garcia CRS, Alves E, Pereira PHS, et al. InsP3 Signaling in Apicomplexan Parasites. *Current Topics in Medicinal Chemistry*. 2017;17 (19). <http://dx.doi.org/10.2174/1568026617666170130121042>
 37. Zhang Y, He F, Chen Z, et al. Melatonin modulates IL-1 β -induced extracellular matrix remodeling in human nucleus pulposus cells and attenuates rat intervertebral disc degeneration and inflammation. *Aging*. 2019;11(22):10499-10512.
 38. Mannino G, Caradonna F, Cruciatu I, Lauria A, Perrone A, Gentile C. Melatonin reduces inflammatory response in human intestinal epithelial cells stimulated by interleukin-1 β . *Journal of Pineal Research*. 2019;67 (3). <http://dx.doi.org/10.1111/jpi.12598>
 39. Gilat M, Coeytaux Jackson A, Marshall NS, et al. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial. *Mov Disord*. 2020;35(2):344-349.
 40. Lv W, Liu C, Yu L, et al. Melatonin Alleviates Neuroinflammation and Metabolic Disorder in DSS-Induced Depression Rats. *Oxid Med Cell Longev*. 2020;2020:1-17.
 41. Paavonen EJ, Nieminen-von Wendt T, Vanhala R, Aronen ET, Von Wendt L. Effectiveness of melatonin in the treatment of sleep disturbances in children with asperger disorder. *J Child Adolesc Psychopharmacol*. 2003;13(1):83-95.
 42. Lian C, Wu Z, Gao B, et al. Melatonin reversed tumor necrosis factor- α -inhibited osteogenesis of human mesenchymal stem cells by stabilizing SMAD1 protein. *J Pineal Res*. 2016;61(3):317-327.
 43. Morabito R, Remigante A, Marino A. Melatonin Protects Band 3 Protein in Human Erythrocytes against H₂O₂-Induced Oxidative Stress. *Molecules*. 2019;24(15):2741.
 44. Liu Y-J, Ji D-M, Liu Z-B, et al. Melatonin maintains mitochondrial membrane potential and decreases excessive intracellular Ca²⁺ levels in immature human oocytes. *Life Sci*. 2019;235:116810.
 45. Zou H, Chen B, Ding D, et al. Melatonin promotes the development of immature oocytes from the COH cycle into healthy offspring by protecting mitochondrial function. *Journal of Pineal Research*. 2020;68 (1). <http://dx.doi.org/10.1111/jpi.12621>
 46. Tan DX, Manchester LC, Liu X, Rosales-Corral SA, Acuna-Castroviejo D, Reiter RJ. Mitochondria and chloroplasts as the original sites of melatonin synthesis: A hypothesis related to melatonin's primary function and evolution in eukaryotes. *J Pineal Res*. 2013;54(2):127-138.
 47. Manchester LC, Coto-Montes A, Boga JA, et al. Melatonin: An ancient molecule that makes oxygen metabolically tolerable. *J Pineal Res*. 2015;59(4):403-419.
 48. Rijo-Ferreira F, Acosta-Rodriguez VA, Abel JH, et al. The malaria parasite has an intrinsic clock. *Science*. 2020;368(6492):746-753.
 49. Smith LM, Motta FC, Chopra G, et al. An intrinsic oscillator drives the blood stage cycle of the malaria parasite *Plasmodium falciparum*. *Science*. 2020;368(6492):754-759.
 50. Subudhi AK, O'Donnell AJ, Ramaprasad A, et al. Malaria parasites regulate intra-erythrocytic development duration via serpentine receptor 10 to coordinate with host rhythms. *Nature Communications*. 2020;11 (1). <http://dx.doi.org/10.1038/s41467-020-16593-y>
 51. Koyama FC, Carvalho TLG, Alves E, Henrique B. The structurally related auxin and melatonin tryptophan-derivatives and their roles in *Arabidopsis thaliana* and in the human malaria parasite *Plasmodium falciparum*. *J Eukaryot Microbiol*. 2013;60(6):646-651.
 52. Teguh SC, Klonis N, Duffy S, et al. Novel conjugated quinoxaline-indoles compromise *Plasmodium falciparum* mitochondrial function and show promising antimalarial activity. *J Med Chem*. 2013;56(15):6200-6215.
 53. Fernandez LS, Buchanan MS, Carroll AR, Feng YJ, Quinn RJ, Avery VM. Flinderolides A–C: Antimalarial Bis-indole Alkaloids from *Flindersia* species. *Organic Letters*. 2009;11(2):329–332. <http://dx.doi.org/10.1021/ol802506n>
 54. Kgokong JL, Smith PP, Matsabisa GM. 1,2,4-Triazino-[5,6b]indole derivatives: Effects of the trifluoromethyl group on in vitro antimalarial activity. *Bioorganic Med Chem*. 2005;13(8):2935-2942.
 55. Agarwal A, Srivastava K, Puri SK, Chauhan PMS. Syntheses of 2,4,6-trisubstituted triazines as antimalarial agents. *Bioorganic Med Chem Lett*. 2005;15(3):531-533.
 56. Schuck DC, Jordão AK, Nakabashi M, Cunha AC, Ferreira VF, Garcia CRS. Synthetic indole and melatonin derivatives exhibit antimalarial activity on the cell cycle of the human malaria parasite *Plasmodium falciparum*. *Eur J Med Chem*. 2014;78:375-382.
 57. Luthra T, Nayak AK, Bose S, Chakrabarti S, Gupta A, Sen S. Indole based antimalarial compounds targeting the melatonin pathway: Their design, synthesis and biological evaluation. *Eur J Med Chem*. 2019;168:11-27.
 58. Svogie AL, Isaacs M, Hoppe HC, Khanye SD, Veale CGL. Indolyl-3-ethanone- α -thioethers: A promising new class of non-toxic antimalarial agents. *Eur J Med Chem*. 2016;114:79-88.
 59. Lungu MJ, Chisango RL, Weyers C, et al. Expanding the SAR of Nontoxic Antiplasmodial Indolyl-3-ethanone Ethers and Thioethers. *ChemMedChem*. 2018;13(13):1353-1362.
 60. Fang P, Han H, Wang J, Chen K, Chen X, Guo M. Structural Basis for Specific Inhibition of tRNA Synthetase by an ATP Competitive Inhibitor. *Chem Biol*. 2015;22(6):734-744.
 61. Fang P, Yu X, Jeong SJ, et al. Structural basis for full-spectrum inhibition of translational functions on a tRNA synthetase. *Nature Communications*. 2015;6 (1). <http://dx.doi.org/10.1038/ncomms7402>
 62. Hoepfner D, McNamara CW, Lim CS, et al. Selective and specific inhibition of the *plasmodium falciparum* lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. *Cell Host Microbe*. 2012;11(6):654-663.
 63. Istvan ES, Dharia NV, Bopp SE, Gluzman I, Winzler EA, Goldberg DE. Validation of isoleucine utilization targets in *Plasmodium falciparum*. *Proc Natl Acad Sci U S A*. 2011;108(4):1627-1632.
 64. Jackson KE, Pham JS, Kwek M, et al. Dual targeting of aminoacyl-tRNA synthetases to the apicoplast and cytosol in *Plasmodium falciparum*. *Int J Parasitol*. 2012;42(2):177-186.
 65. Zhou H, Sun L, Yang XL, Schimmel P. ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase. *Nature*. 2013;494(7435):121-124.
 66. Novoa EM, Camacho N, Tor A, et al. Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo. *Proc Natl Acad Sci U S A*. 2014;111(51):E5508-E5517.
 67. Pasaje CFA, Cheung V, Kennedy K, et al. Selective inhibition of apicoplast tryptophanyl-tRNA synthetase causes delayed death in *Plasmodium falciparum*. *Scientific Reports*. 2016;6 (1). <http://dx.doi.org/10.1038/srep27531>

68. Uddin T, McFadden GI, Goodman CD. Validation of Putative Apicoplast-Targeting Drugs Using a Chemical Supplementation Assay in Cultured Human Malaria Parasites. *Antimicrobial Agents and Chemotherapy*. 2017;62 (1). <http://dx.doi.org/10.1128/aac.01161-17>
69. Eklund EH, Schneider J, Fidock DA. Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches. *FASEB J*. 2011;25(10):3583-3593.
70. Goodman CD, Su V, McFadden GI. The effects of anti-bacterials on the malaria parasite *Plasmodium falciparum*. *Mol Biochem Parasitol*. 2007;152(2):181-191.
71. Kennedy K, Cobbold SA, Hanssen E, et al. Delayed death in the malaria parasite *Plasmodium falciparum* is caused by disruption

of prenylation-dependent intracellular trafficking. *PLOS Biol*. 2019;17(7):e3000376.

How to cite this article: Pereira PHS, Garcia CRS. Melatonin action in *Plasmodium* infection: Searching for molecules that modulate the asexual cycle as a strategy to impair the parasite cycle. *J Pineal Res*. 2020;00:e12700. <https://doi.org/10.1111/jpi.12700>